Das Rezūm-System in der Behandlung der Blasenentleerungsstörung auf dem Boden einer gutartigen Prostatavergrößerung (BPO)

Zusammenfassung

Der klassische Therapiealgorithmus zur Behandlung des benignen Prostatasyndroms (BPS) beinhaltet bei Versagen der medikamentösen Therapie einen chirurgischen Ansatz. Neue minimalinvasive Therapien (MIT) bieten das Potenzial für eine schnelle Symptomlinderung bei gleichzeitiger Reduzierung der mit den invasiven Verfahren assoziierten perioperativen Morbidität. Die konvektive interstitielle Radiofrequenz-generierte Wasserdampf-Thermoablation der Prostata mit dem Rezūm^®-System ist ein neuartiges MIT zur Behandlung von Männern mit moderaten bis schweren LUTS. Es ermöglicht eine schnelle und dauerhafte Linderung von Speicher- und Entleerungs-LUTS, das Erhalten unzerstörter Sexualfunktion (in Bezug auf sowohl Erektion als auch Ejakulation) und die Verbesserung der Lebensqualität. Das Verfahren bietet sich für die Behandlung eines breiten Spektrums von Prostatadrüsenmorphologien einschließlich intravesikaler Prostataprotrusion, Mittellappen- oder Blasenhalselevation durch zentrale Hyperplasie. Das Rezūm-Verfahren kann auch als Erstlinientherapie zur Krankheitsprogressionsvorbeugung als Alternative zur medikamentösen Langzeit-Polytherapie bei selektionierten Patienten angesetzt werden, um mögliche medikamentenassoziierte Nebenwirkungen zu vermeiden. Dieser Übersichtsartikel befasst sich mit der Beschreibung dieser neuen Technologie und ihrer klinischen Anwendung sowie mit der aktuellen Evidenz, die die Effektivität, die Sicherheit und die Perspektive des Rezūm-Verfahrens bis zum jetzigen Zeitpunkt unterstützt.

Abstract

The classical algorithm of the management of male lower urinary tract symptoms (LUTSs) due to benign prostatic hyperplasia (BPH) includes a surgical approach in case pharmacological therapy has failed. Emerging minimally-invasive treatments (MITs) offer potential for rapid symptomatic relief, reducing the morbidity of invasive BPH surgery. Convective interstitial radiofrequency water vapour thermal ablation of the prostate with the Rezūm^® system is a novel MIT for the treatment of bothersome moderate-to-severe lower urinary tract symptoms associated with BPH. It provides early effective and durable relief of storage and voiding LUTSs, preserving both erectile and ejaculatory function and improving quality of life. The procedure allows the treatment of a wide spectrum of prostate gland morphologies including intravesical prostatic protrusion, median lobe protrusion or elevated bladder neck. In selected patients, this procedure can also be offered for first-line treatment to prevent symptom progression and may thus be used as an alternative to long-term pharmaceutical treatment in order to avoid potential side-effects of drugs. This review describes this new technology and its clinical application and presents the current clinical evidence that supports the efficacy, safety and prospects of the Rezūm procedure to date.

Schlüsselwörter

Prostata - Benignes Prostatasyndrom - Symptome des unteren Harntrakts - konvektive RF-Wärmetherapie - minimalinvasive Verfahren

Keywords

prostate - benign prostatic hyperplasia - lower urinary tract symptoms - convective RF thermal therapy - minimally-invasive procedure

• Literatur

• 1 Irwin DE, Milsom I, Hunskaar S. et al. Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study. Eur Urol 2006; DOI: 10.1016/j.eururo.2006.09.019.
• 2 Alexander EE, Lewitton M, Light RA. et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Reports Urol 2017; 9: 159-168
• 3 Blanker MH, Groeneveld FPMJ, Prins A. et al. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: The Krimpen study of male urogenital tract problems and general health status. BJU Int 2000; 85: 665-671
• 4 Nickel JC. BPH: costs and treatment outcomes. Am J Manag Care 2006; 12 (Suppl. 05) 141-148
• 5 Rensing AJ, Kuxhausen A, Vetter J. et al. Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist. Urol Pract 2017; DOI: 10.1016/j.urpr.2016.07.002.
• 6 Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clin Outcomes Res 2018; 10: 29-43
• 7 Woo HH, Gonzalez RR. Perspective on the Rezūm^® system: A minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Devices Evid Res 2017; 10: 71-80
• 8 McVary KT, Roehrborn CG. Three-Year Outcomes of the Prospective, Randomized Controlled Rezūm System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Urology 2018; 111: 1-9
• 9 McVary KT, Gange SN, Gittelman MC. et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of LUTS secondary to BPH: randomized controlled study. J Sex Med 2016; 13: 924-933
• 10 Oelke M, Martinelli E. Medikamentöse Therapie des benignen Prostatasyndroms. Urologe 2016; 55: 81-96
• 11 Christidis D, McGrath S, Perera M. et al. Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. Prostate Int 2017; 5: 41-46
• 12 Gravas S, Bach T, Bachmann A. et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Eur Assoc Guidel 2015; DOI: 10.1016/j.eururo.2014.12.038.
• 13 Dixon CM, Cedano ER, Mynderse LA. et al. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the rezūm^® system: Evaluation of acute ablative capabilities in the human prostate. Res Reports Urol 2015; 7: 13-18
• 14 Bhowmick P, Coad JE, Bhowmick S. et al. In vitro assessment of the efficacy of thermal therapy in human benign prostatic hyperplasia. Int J Hyperth 2004; DOI: 10.1080/02656730310001637343\r15BBU196XL8F5MQG.
• 15 McNeal JE. The zonal anatomy of the prostate. Prostate 1981; DOI: 10.1002/pros.2990020105.
• 16 McVary KT, Gange SN, Gittelman MC. et al. Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016; 195: 1529-1537
• 17 Dixon CM, Cedano ER, Larson TR. et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016; DOI: 10.2147/RRU.S119596.
• 18 Dixon C, Cedano ijo ER, Pacik D. et al. Efficacy and Safety of Rezūm System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Urology 2015; 86: 1042-1047
• 19 Mynderse LA, Hanson D, Robb RA. et al. Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 2015; 86: 122-127
• 20 Roehrborn CG, Gange SN, Gittelman MC. et al. Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. J Urol 2017; 197: 1507-1516
• 21 Pathak P, Helo S, McVary KT. What’s New in Rezum?. Eur Urol Focus 2018; 4: 3-6
• 22 Gupta N, Holland B, Dynda D. et al. Pd27-02 Comparison of Convective Radiofrequency Water Vapor Energy Ablation of Prostate (Rezum^®) To Mtops Trial Cohort. J Urol 2017; 197: e511
• 23 McConnell JD, Roehrborn CG, Bautista OM. et al. M. for the MT of PS (MTOPS) RG, Abstract. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. N Engl J Med 2003; DOI: 10.1056/NEJMoa1208410.